Poštovane/Poštovani, u nastavku pročitajte Priopćenje za medije Hrvatske udruge leukemija i limfomi (HULL), sa sjedištem u Zagrebu, Trg hrvatskih velikana 2/2, OIB: 51774844072, a odnosi se na nedostatak intravenskog imonoglobulina (Intravenous Immunoglobulin Therapy) – dalje IVlg, u bolnicama, pripravka potrebnog za liječenje leukemija i limfoma, kao i drugih rijetkih bolesti. […]
U povodu Svjetskog dana borbe protiv raka (World Cancer Day), 4. veljače, Odbor za zdravstvo i socijalnu politiku Hrvatskoga sabora na inicijativu Koalicije udruga u zdravstvu organizira tematsku sjednicu 3. veljače (četvrtak) 2022. u 11.00 sati na kojoj bi se razmotrila problematika onkološke skrbi u uvjetima pandemije COVID-19, s posebnim osvrtom na Nacionalni strateški okvir protiv raka (NSOPR), koji je Hrvatski sabor usvojio 15. prosinca 2020. Tematsku sjednicu pratite ovdje.
[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" menu_anchor="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" class="" id="" background_color="" background_image="" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_mp4="" video_webm="" video_ogv="" video_url="" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" overlay_color="" video_preview_image="" border_color="" border_style="solid" padding_top="" padding_bottom="" padding_left="" padding_right=""][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" align_self="auto" content_layout="column" align_content="flex-start" valign_content="flex-start" content_wrap="wrap" spacing="yes" center_content="no" link="" target="_self" link_description="" min_height="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" class="" id="" background_image_id="" type_medium="" type_small="" order_medium="0" order_small="0" spacing_left_medium="" spacing_right_medium="" spacing_left_small="" spacing_right_small="" spacing_left="" spacing_right="" margin_top_medium="" margin_bottom_medium="" margin_top_small="" margin_bottom_small="" margin_top="0px" margin_bottom="0px" padding_top_medium="" padding_right_medium="" padding_bottom_medium="" padding_left_medium="" padding_top_small="" padding_right_small="" padding_bottom_small="" padding_left_small="" padding_top="30px" padding_right="30px" padding_bottom="30px" padding_left="30px" hover_type="none" border_sizes_top="" border_sizes_right="" border_sizes_bottom="" border_sizes_left="" border_color="" hue="" saturation="" lightness="" alpha="" border_style="solid" border_radius_top_left="" border_radius_top_right="" border_radius_bottom_right="" border_radius_bottom_left="" box_shadow="no" box_shadow_vertical="" box_shadow_horizontal="" box_shadow_blur="0" box_shadow_spread="0" box_shadow_color="" box_shadow_style="" overflow="" background_type="single" gradient_start_color="" gradient_end_color="" gradient_start_position="0" gradient_end_position="100" gradient_type="linear" radial_direction="center center" linear_angle="180" background_color="#4a4e57" background_image="" background_position="left top" background_repeat="no-repeat" background_blend_mode="none" render_logics="" filter_type="regular" filter_hue="0" filter_saturation="100" filter_brightness="100" filter_contrast="100" filter_invert="0" filter_sepia="0" filter_opacity="100" filter_blur="0" filter_hue_hover="0" filter_saturation_hover="100" filter_brightness_hover="100" filter_contrast_hover="100" filter_invert_hover="0" filter_sepia_hover="0" filter_opacity_hover="100" filter_blur_hover="0" animation_type="" animation_direction="left" animation_speed="0.3" animation_offset="" last="true" border_position="all" first="true"][fusion_text columns="" column_min_width="" column_spacing="" rule_style="default" rule_size="" rule_color="" hue="" saturation="" lightness="" alpha="" content_alignment_medium="" content_alignment_small="" content_alignment="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" [...]
[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" menu_anchor="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" class="" id="" background_color="" background_image="" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_mp4="" video_webm="" video_ogv="" video_url="" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" overlay_color="" video_preview_image="" border_color="" border_style="solid" padding_top="" padding_bottom="" padding_left="" padding_right=""][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" align_self="auto" content_layout="column" align_content="flex-start" valign_content="flex-start" content_wrap="wrap" spacing="yes" center_content="no" link="" target="_self" link_description="" min_height="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" class="" id="" background_image_id="" type_medium="" type_small="" order_medium="0" order_small="0" spacing_left_medium="" spacing_right_medium="" spacing_left_small="" spacing_right_small="" spacing_left="" spacing_right="" margin_top_medium="" margin_bottom_medium="" margin_top_small="" margin_bottom_small="" margin_top="0px" margin_bottom="0px" padding_top_medium="" padding_right_medium="" padding_bottom_medium="" padding_left_medium="" padding_top_small="" padding_right_small="" padding_bottom_small="" padding_left_small="" padding_top="30px" padding_right="30px" padding_bottom="30px" padding_left="30px" hover_type="none" border_sizes_top="" border_sizes_right="" border_sizes_bottom="" border_sizes_left="" border_color="" hue="" saturation="" lightness="" alpha="" border_style="solid" border_radius_top_left="" border_radius_top_right="" border_radius_bottom_right="" border_radius_bottom_left="" box_shadow="no" box_shadow_vertical="" box_shadow_horizontal="" box_shadow_blur="0" box_shadow_spread="0" box_shadow_color="" box_shadow_style="" overflow="" background_type="single" gradient_start_color="" gradient_end_color="" gradient_start_position="0" gradient_end_position="100" gradient_type="linear" radial_direction="center center" linear_angle="180" background_color="#4a4e57" background_image="" background_position="left top" background_repeat="no-repeat" background_blend_mode="none" render_logics="" filter_type="regular" filter_hue="0" filter_saturation="100" filter_brightness="100" filter_contrast="100" filter_invert="0" filter_sepia="0" filter_opacity="100" filter_blur="0" filter_hue_hover="0" filter_saturation_hover="100" filter_brightness_hover="100" filter_contrast_hover="100" filter_invert_hover="0" filter_sepia_hover="0" filter_opacity_hover="100" filter_blur_hover="0" animation_type="" animation_direction="left" animation_speed="0.3" animation_offset="" last="true" border_position="all" first="true"][fusion_text columns="" column_min_width="" column_spacing="" rule_style="default" rule_size="" rule_color="" hue="" saturation="" lightness="" alpha="" content_alignment_medium="" content_alignment_small="" content_alignment="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" [...]
[fusion_builder_container type="flex" hundred_percent="no" equal_height_columns="no" menu_anchor="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" class="" id="" background_color="" background_image="" background_position="center center" background_repeat="no-repeat" fade="no" background_parallax="none" parallax_speed="0.3" video_mp4="" video_webm="" video_ogv="" video_url="" video_aspect_ratio="16:9" video_loop="yes" video_mute="yes" overlay_color="" video_preview_image="" border_color="" border_style="solid" padding_top="" padding_bottom="" padding_left="" padding_right=""][fusion_builder_row][fusion_builder_column type="1_1" layout="1_1" align_self="auto" content_layout="column" align_content="flex-start" valign_content="flex-start" content_wrap="wrap" spacing="yes" center_content="no" link="" target="_self" link_description="" min_height="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" class="" id="" background_image_id="" type_medium="" type_small="" order_medium="0" order_small="0" spacing_left_medium="" spacing_right_medium="" spacing_left_small="" spacing_right_small="" spacing_left="" spacing_right="" margin_top_medium="" margin_bottom_medium="" margin_top_small="" margin_bottom_small="" margin_top="0px" margin_bottom="0px" padding_top_medium="" padding_right_medium="" padding_bottom_medium="" padding_left_medium="" padding_top_small="" padding_right_small="" padding_bottom_small="" padding_left_small="" padding_top="30px" padding_right="30px" padding_bottom="30px" padding_left="30px" hover_type="none" border_sizes_top="" border_sizes_right="" border_sizes_bottom="" border_sizes_left="" border_color="" hue="" saturation="" lightness="" alpha="" border_style="solid" border_radius_top_left="" border_radius_top_right="" border_radius_bottom_right="" border_radius_bottom_left="" box_shadow="no" box_shadow_vertical="" box_shadow_horizontal="" box_shadow_blur="0" box_shadow_spread="0" box_shadow_color="" box_shadow_style="" overflow="" background_type="single" gradient_start_color="" gradient_end_color="" gradient_start_position="0" gradient_end_position="100" gradient_type="linear" radial_direction="center center" linear_angle="180" background_color="#4a4e57" background_image="" background_position="left top" background_repeat="no-repeat" background_blend_mode="none" render_logics="" filter_type="regular" filter_hue="0" filter_saturation="100" filter_brightness="100" filter_contrast="100" filter_invert="0" filter_sepia="0" filter_opacity="100" filter_blur="0" filter_hue_hover="0" filter_saturation_hover="100" filter_brightness_hover="100" filter_contrast_hover="100" filter_invert_hover="0" filter_sepia_hover="0" filter_opacity_hover="100" filter_blur_hover="0" animation_type="" animation_direction="left" animation_speed="0.3" animation_offset="" last="true" border_position="all" first="true"][fusion_text columns="" column_min_width="" column_spacing="" rule_style="default" rule_size="" rule_color="" hue="" saturation="" lightness="" alpha="" content_alignment_medium="" content_alignment_small="" content_alignment="" hide_on_mobile="small-visibility,medium-visibility,large-visibility" sticky_display="normal,sticky" [...]
Udruga MijelomCRO nastavlja tradiciju dragocijenih susreta oboljelih od mijeloma i članova njihovih obitelji s liječnicima i pružateljima medicinske skrbi, koji će se ove godine, zbog još uvijek nepovoljnih epidemioloških uvjeta usljed pandemije koronavirusa, održati virtualno u subotu, 18. prosinca 2021. od 17:30-19:30h putem aplikacije ZOOM. […]
Poštovana/i, zadovoljstvo nam je obavijestiti Vas da je Hrvatsko društvo za bolesti jetre „Hepatos“ domaćin društveno odgovorne inicijative MedTalk-a koja se organizira u sklopu Mjeseca borbe protiv raka jetre. […]
U rujnu, mjesecu koji je širom svijeta posvećen podizanju svijesti o raku krvi, Udruga pacijenata MijelomCRO apelira na javnost i zdravstveni sustav da prepoznaju aktualni težak položaj oboljelih od multiplog mijeloma, rijetkog oblika raka krvi od kojega u Hrvatskoj boluje oko 750 ljudi. Pogođeni mijelomom imaju drastično oslabljen imunitet. Njihove plazma stanice ne proizvode normalan broj i kvalitetu antitijela, pa im je tijelo, koje se i inače teško bori s infekcijama, podvrgnuto naporima. U slučaju obolijevanja od virusne bolesti Covid-19 imaju veće izglede za komplikacije i teške ishode. Raste im vjerojatnost za kraće preživljenje, a svaki prerani smrtni ishod je nečiji osobni gubitak. Postoje mnoge nepoznanice i dileme. Ali postoje i činjenice, bjelodane i očite. Našim članovima, oboljelima od multiplog mijeloma, raka krvi, pandemijska situacija je ozbiljno narušila sigurnost i povećala rizike od nevolja. SITUACIJA SE POGORŠAVA, OPASNI RIZICI RASTU Godinu i pol od izbijanja pandemije koronavirusa, oboljeli od mijeloma i drugih oblika raka krvi žive [...]
Dragi svi, Europska zaklade za pluća (eng. European Lung Foundation), i radna skupina za fragilnost Europskog respiratornog društva (eng. European Respiratory Society), zamolili su nas da podijelimu anketu koja se bavi iskustvom života s fragilnošću i kroničnim plućnim bolestima kao što su kronična opstruktivna plućna bolest (KOPB), astma, bronhiektazije ili plućna fibroza. Ako sami imate zdravstvenih problema (vrijedi i za osobe s tumorom pluća), ili brinete o osobi s kroničnom plućnom bolešću, molimo vas da ispunite anketu (sva su pitanja prevedena na hrvatski jezik). Ispunjavanje ankete uzet će samo pet minuta vašeg vremena, a vrijednost dobivenih rezultata je višestruka. Hvala! https://www.surveymonkey.co.uk/r/frailty_survey?lang=hr
Agencija za lijekove i medicinske proizvode (HALMED) uključena je u neintervencijsko ispitivanje pod nazivom Prospektivno praćenje sigurnosti cjepiva protiv bolesti COVID-19 u Europi na temelju ishoda koje su prijavile cijepljene osobe, koje se provodi na razini Europske unije u sklopu projekta vACCine covid-19 monitoring readinESS (ACCESS). Naručitelj ispitivanja je Europska agencija za lijekove. Riječ je o prospektivnom intenzivnom praćenju cjepiva protiv bolesti COVID-19 koje omogućuje prikupljanje podataka o cjepivima, uključujući podatke o nuspojavama nakon cijepljenja, njihovom tijeku i ishodu, težini i ozbiljnosti te potencijalnim čimbenicima rizika, izravno od cijepljenih osoba u gotovo stvarnom vremenu. Prikupljanje podataka o cjepivima protiv bolesti COVID-19 nakon stavljanja u promet od iznimne je važnosti za kontinuirano praćenje njihovih sigurnosnih profila. Iako su prije davanja odobrenja ova cjepiva temeljito ispitana, u klinička ispitivanja provedena u svrhu davanja odobrenja uključen je ograničen broj ispitanika te nisu obuhvaćene posebne skupine, kao što su bolesnici s visokorizičnim popratnim bolestima, posebice imunokompromitirani bolesnici ili trudnice. [...]
